BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Chinese Patent Office
Chubb
Medtronic
Daiichi Sankyo
Citi
US Army
Cipla
Baxter

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,225,445

« Back to Dashboard

Summary for Patent: 5,225,445
Title: Phenethanolamine derivatives having .beta..sub.2 -adrenoreceptor selective stimulant action
Abstract:Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.
Inventor(s): Skidmore; Ian F. (Welwyn, GB2), Lunts; Lawrence H. C. (Broxbourne, GB2), Finch; Harry (Hitchin, GB2), Naylor; Alan (Royston, GB2)
Assignee: Glaxo Group Ltd. (London)
Application Number:07/837,783
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 5,225,445

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,225,445

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8310477Apr 18, 1983
United Kingdom8317087Jun 23, 1983
United Kingdom8329560Nov 04, 1983
United Kingdom8401809Jan 25, 1984

International Patents Family Members for US Patent 5,225,445

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom 2140800 ➤ Subscribe
France 2545482 ➤ Subscribe
United Kingdom 8410124 ➤ Subscribe
United Kingdom 8310477 ➤ Subscribe
United Kingdom 8317087 ➤ Subscribe
United Kingdom 8329568 ➤ Subscribe
Denmark 175083 ➤ Subscribe
Czech Republic 9104028 ➤ Subscribe
Czech Republic 285602 ➤ Subscribe
Germany 3414752 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
Citi
Accenture
Fish and Richardson
Julphar
Queensland Health
Mallinckrodt
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot